---
title: "Regentis Biomaterials Appoints Ori Gon as CFO and Chief Business Officer"
description: "Regentis Biomaterials Ltd. has appointed Ori Gon as Chief Financial Officer and Chief Business Officer. Gon will manage commercial and business development activities, along with financial strategy, p"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/274964582.md"
published_at: "2026-02-05T11:43:31.000Z"
---

# Regentis Biomaterials Appoints Ori Gon as CFO and Chief Business Officer

> Regentis Biomaterials Ltd. has appointed Ori Gon as Chief Financial Officer and Chief Business Officer. Gon will manage commercial and business development activities, along with financial strategy, planning, and reporting, as the company prepares for the commercial launch of GelrinC in Europe and advances its U.S. Phase III FDA trial.

Regentis Biomaterials Ltd. has appointed Ori Gon as Chief Financial Officer and Chief Business Officer. Gon will oversee commercial and business development activities, as well as financial strategy, planning, and reporting, as the company prepares for the commercial launch of GelrinC in Europe and advances its U.S. Phase III FDA trial. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regentis Biomaterials Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-012525), on February 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [RGNT.US - Regentis Biomaterials](https://longbridge.com/en/quote/RGNT.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Regentis Biomaterials 任命主席 Ehud Geller 擔任首席執行官 | Regentis Biomaterials Ltd. 宣佈首席執行官 Eli Hazum 博士因個人原因立即辭職。董事會主席 Ehud Geller 博士被任命為新首席執行官 | [Link](https://longbridge.com/en/news/271654996.md) |
| Regentis 的 GelrinC 通過定量 MOCART 評估證明了軟骨修復的長期耐久性 \| RGNT 股票新聞 | Regentis Biomaterials 發佈了其 GelrinC 第二階段臨牀試驗的長期結果，顯示出顯著的軟骨修復效果，採用 MOCART 評估。研究顯示，在 24 個月時的平均 MOCART 得分為 88.8，表明幾乎完全的結構修復。 | [Link](https://longbridge.com/en/news/271657008.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.